Yale IRB Approval Clears Path for Parts B and C of Clearmind Medicine's CMND-100 Trial
CMND is trading near its 52-week low of $1.16 (0.0% above the low) on elevated volume (21× avg).
Summary
Clearmind Medicine received Yale IRB approval to begin patient recruitment for Parts B and C of its CMND-100 Phase I/II trial in alcohol use disorder, adding Yale to Johns Hopkins and two Israeli sites.
Key Events · Product Development and Regulatory · CMND
-
Yale IRB Approval Received
Yale University's IRB has approved initiation of patient recruitment for Parts B and C of the CMND-100 Phase I/II trial in alcohol use disorder.
-
Fourth Trial Site Added
Yale now joins Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center as actively recruiting sites.
-
Trial Leadership at Yale
The Yale site is led by Anahita Bassir Nia, MD, a specialist in psychiatry and addiction medicine.
-
Part A Safety Results Reaffirmed
All 24 participants in Part A completed treatment per protocol with no serious adverse events; the primary safety and tolerability endpoint was met.
Analysis · CMND · Life Sciences
Approval from Yale's IRB marks a concrete regulatory step that brings a fourth major site into the CMND-100 Phase I/II trial and opens recruitment for Parts B and C. The move builds on positive Part A safety results and edges the program closer to efficacy data in AUD patients. For a micro-cap trading near its 52-week low with a going-concern warning, clinical progress is the primary value driver.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $1.16 to $524.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.